Search

Your search keyword '"Bader, P"' showing total 355 results
Start Over Author "Bader, P" Journal bone marrow transplantation
355 results on '"Bader, P"'

1. Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT

Author

Aldebert, Clémence, Fahd, Mony, Galimard, Jacques-Emmanuel, Ghemlas, Ibrahim A., Zecca, Marco, Silva, Juliana, Mohseny, Alexander, Kupesiz, Alphan, Hamladji, Rose-Marie, Miranda, Nuno, Güngör, Tayfun, Wynn, Robert F., Merli, Pietro, Sundin, Mikael, Faraci, Maura, Diaz-de-Heredia, Cristina, Burkhardt, Birgit, Bordon, Victoria, Angoso, Marie, Bader, Peter, Ifversen, Marianne, Herrera Arroyo, Concepcion, Maximova, Natalia, Riesco, Susana, Stein, Jerry, Dalissier, Arnaud, Locatelli, Franco, Kalwak, Krzysztof, Dalle, Jean-Hugues, and Corbacioglu, Selim

Abstract

Congenital amegakaryocytic thrombocytopenia is a rare, inherited bone marrow failure syndrome. Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. In this retrospective study, we analysed 66 patients with allo-HSCT, reported in the European Society for Blood and Marrow Transplantation (EBMT) registry. Bone marrow (BM) was the most widely used stem cell source (n= 40; 61%) followed by peripheral blood (PB) (n= 18; 27%), and unrelated umbilical cord blood (UCB) (n= 8; 12%). Most frequently was a HLA-matched graft from related (n= 26; 39%) and unrelated (n= 15; 23%) donors after a myeloablative busulfan-based conditioning regimen. GvHD prophylaxis was mostly cyclosporine and methotrexate (53%). The 6-year cumulative incidence of graft-failure and second transplant were 25% and 17%, respectively. The 6-year disease-free survival (DFS) and overall survival (OS) were 66.9% and 85.6%, respectively. The 6-year transplant-related mortality (TRM) was 8.0%. In conclusion, most patients with CAMT benefit from allo-HSCT, but with many graft failures.

Published
2024
Full Text
View/download PDF

2. Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression

Author

Meissner, Barbara, Lang, Peter, Bader, Peter, Hoenig, Manfred, Müller, Ingo, Meisel, Roland, Greil, Johann, Sauer, Martin G., Metzler, Markus, Corbacioglu, Selim, Burkhardt, Birgit, Wölfl, Matthias, Strahm, Brigitte, Kafa, Kinan, Basu, Oliver, Lode, Holger N., Gruhn, Bernd, Cario, Holger, Ozga, Ann-Kathrin, Zimmermann, Martin, Jarisch, Andrea, and Beier, Rita

Abstract

We performed a retrospective analysis on 124 patients with transfusion-dependent thalassemia who were registered in the German pediatric registry for stem cell transplantation. All patients underwent first allogeneic hematopoietic stem cell transplantation (HSCT) between 2011 and 2020 and belonged mainly to Pesaro risk class 1–2. Four-year overall (OS) and thalassemia-free survival (TFS) were 94.5% ± 2.9% and 88.0% ± 3.4% after treosulfan-fludarabine-thiotepa- and 96.9% ± 3.1% (P= 0.763) and 96.9% ± 3.1% (P= 0.155) after busulfan-fludarabine-based conditioning. Mixed chimerism below 75% occurred predominantly in treosulfan-based regimens (27.5% versus 6.2%). OS and TFS did not differ significantly between matched sibling, other matched family and matched unrelated donor (UD) HSCTs (OS: 100.0%, 100.0%, 96.3% ± 3.6%; TFS: 96.5% ± 2.4%, 90.0% ± 9.5%, 88.9% ± 6.0%). However, mismatched UD-HSCTs performed less favorable (OS: 84.7% ± 7.3% (P= 0.029); TFS: 79.9% ± 7.4% (P= 0.082)). We generated a scoring system reflecting the risk to develop mixed chimerism in our cohort. The main risk-reducing factors were a high CD3+ cell count (≥6 × 107/kg) in the graft, busulfan-conditioning, pre-conditioning therapy and low-targeted ciclosporin A trough levels. Acute GvHD grade III-IV in treosulfan-based concepts predominantly occurred in patients with UD and reduced GvHD prophylaxis but not in the context of high CD3+ cell doses. Taken together, this information might be used to develop more risk-adapted HSCT regimens for thalassemia patients.

Published
2024
Full Text
View/download PDF

5. Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group

Author

Balduzzi, A, Dalle, J-H, Jahnukainen, K, von Wolff, M, Lucchini, G, Ifversen, M, Macklon, K T, Poirot, C, Diesch, T, Jarisch, A, Bresters, D, Yaniv, I, Gibson, B, Willasch, A M, Fadini, R, Ferrari, L, Lawitschka, A, Ahler, A, Sänger, N, Corbacioglu, S, Ansari, M, Moffat, R, Dalissier, A, Beohou, E, Sedlacek, P, Lankester, A, De Heredia Rubio, C D, Vettenranta, K, Wachowiak, J, Yesilipek, A, Trigoso, E, Klingebiel, T, Peters, C, Bader, P, and Transplantation, Marrow

Published
2017
Full Text
View/download PDF

8. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors

Author

Styczynski, J., Tridello, G., Koster, L., Iacobelli, S., Biezen, A. van, Werf, S. van der, Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., Camara, R. de la, Baldomero, H., Bader, P., Basak, G., Bonini, C., Duarte, R., Dufour, C., Kuball, J., Lankester, A., Montoto, S., Nagler, A., Snowden, J.A., Kroger, N., Mohty, M., Gratwohl, A., Infect Dis Working Party EBMT, UAM. Departamento de Medicina, Styczynski, J., Tridello, G., Koster, L., Iacobelli, S., van Biezen, A., van der Werf, S., Mikulska, M., Gil, L., Cordonnier, C., Ljungman, P., Averbuch, D., Cesaro, S., de la Camara, R., Baldomero, H., Bader, P., Basak, G., Bonini, C., Duarte, R., Dufour, C., Kuball, J., Lankester, A., Montoto, S., Nagler, A., Snowden, J. A., Kroger, N., Mohty, M., and Gratwohl, A.

Subjects
medicine.medical_specialty, Medicina, Epidemiology, medicine.medical_treatment, Hematopoietic stem cell transplantation, Disease, Infections, survival, Communicable Diseases, Article, Cohort Studies, cause of death, Internal medicine, stem cell transplant, medicine, Humans, Haematopoietic stem cell transplantation (HSCT), Risk factor, Cause of death, Transplantation, Leukemia, stem cell transplant, cause of death, survival, business.industry, Incidence (epidemiology), Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Settore MED/15, Death, Settore MED/01, surgical procedures, operative, Risk factors, Mycoses, Cohort, business, Cohort study
Abstract

Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980–2001) to cohort 2 (2002–2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of “unknown origin”., The study was funded by the European Group for Blood and Marrow Transplantation EBMT

Published
2019
Full Text
View/download PDF

11. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)

Author

Mohty, Mohamad, Malard, Florent, Alaskar, Ahmed S., Aljurf, Mahmoud, Arat, Mutlu, Bader, Peter, Baron, Frederic, Bazarbachi, Ali, Blaise, Didier, Brissot, Eolia, Ciceri, Fabio, Corbacioglu, Selim, Dalle, Jean-Hugues, Dignan, Fiona, Huynh, Anne, Kenyon, Michelle, Nagler, Arnon, Pagliuca, Antonio, Perić, Zinaida, Richardson, Paul G., Ruggeri, Annalisa, Ruutu, Tapani, Yakoub-Agha, Ibrahim, Duarte, Rafael F., and Carreras, Enric

Abstract

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). A new definition for diagnosis, and a severity grading system for SOS/VOD in adult patients, was reported a few years ago on behalf of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this work is to update knowledge regarding diagnosis and severity assessment of SOS/VOD in adult patients, and also its pathophysiology and treatment. In particular, we now propose to refine the previous classification and distinguish probable, clinical and proven SOS/VOD at diagnosis. We also provide an accurate definition of multiorgan dysfunction (MOD) for SOS/VOD severity grading based on Sequential Organ Failure Assessment (SOFA) score.

Published
2023
Full Text
View/download PDF

15. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)

Subjects
Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019
Full Text
View/download PDF

18. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Author

Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, and Carreras, E

Published
2015
Full Text
View/download PDF

23. Correction to: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., primary, Schober, S. J., additional, Ranft, A., additional, Gassmann, H., additional, Jabar, S., additional, Gall, K., additional, von Lüttichau, I., additional, Wawer, A., additional, Koscielniak, E., additional, Diaz, M. A., additional, Ussowicz, M., additional, Kazantsev, I., additional, Afanasyev, B., additional, Merker, M., additional, Klingebiel, T., additional, Prete, A., additional, Gruhn, B., additional, Bader, P., additional, Jürgens, H., additional, Dirksen, U., additional, Handgretinger, R., additional, Burdach, S., additional, and Lang, P., additional

Published
2021
Full Text
View/download PDF

24. ALLOGENEIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED RHABDOMYOSARCOMA: A RETROSPECTIVE ASSESSMENT: PH-AB118

Author

Thiel, U., Koscielniak, E., Blaeschke, F., Grunewald, T. G. P., Badoglio, M., Diaz, Angel M., Paillard, C., Prete, A., Ussowicz, M., Lang, P., Fagioli, F., Lutz, P., Ehninger, G., Schneider, P., Santucci, A., Bader, P., Gruhn, B., Faraci, M., Antunovic, P., Styczynski, J., Krüger, W. H., Castagna, L., Rohrlich, P., Ouachee, M., Salmon, A., Peters, C., Bregni, M., and Burdach, S.

Published
2014

31. CLINICAL IMPACT OF POST-TRANSPLANT CHIMERISM MONITORING IN CD33/34 BONE MARROW SUBPOPULATIONS AND WHOLE PERIPHERAL BLOOD IN PEDIATRIC AML: PROSPECTIVE COMPARISON OF HIGHLY SENSITIVE REAL TIME SEQUENCE POLYMORPHISM PCR VERSUS GOLD-STANDARD STR-PCR: PH-O097

Author

Willasch, Manfred A., Rettinger, E., Zabel, M., Kreyenberg, H., Meyer, V., Merker, M., Borkhardt, A., Metzler, M., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M., Schlegel, P.-G., Klingebiel, T., and Bader, P.

Published
2014

34. Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial

Author

Sykora, Karl-Walter, Beier, Rita, Schulz, Ansgar, Cesaro, Simone, Greil, Johann, Gozdzik, Jolanta, Sedlacek, Petr, Bader, Peter, Schulte, Johannes, Zecca, Marco, Locatelli, Franco, Gruhn, Bernd, Reinhardt, Dirk, Styczynski, Jan, Piras, Simona, Fagioli, Franca, Bonanomi, Sonia, Caniglia, Maurizio, Li, Xieran, Baumgart, Joachim, Kehne, Jochen, Mielcarek-Siedziuk, Monika, and Kalwak, Krzysztof

Abstract

Optimal conditioning prior to allogeneic hematopoietic stem cell transplantation for children with non-malignant diseases is subject of ongoing research. This prospective, randomized, phase 2 trial compared safety and efficacy of busulfan with treosulfan based preparative regimens. Children with non-malignant diseases received fludarabine and either intravenous (IV) busulfan (4.8 to 3.2 mg/kg/day) or IV treosulfan (10, 12, or 14 g/m2/day). Thiotepa administration (2 × 5 mg/kg) was at the investigator’s discretion. Primary endpoint was freedom from transplantation (treatment)-related mortality (freedom from TRM), defined as death between Days -7 and +100. Overall, 101 patients (busulfan 50, treosulfan 51) with at least 12 months follow-up were analyzed. Freedom from TRM was 90.0% (95% CI: 78.2%, 96.7%) after busulfan and 100.0% (95% CI: 93.0%, 100.0%) after treosulfan. Secondary outcomes (transplantation-related mortality [12.0% versus 3.9%]) and overall survival (88.0% versus 96.1%) favored treosulfan. Graft failure was more common after treosulfan (n = 11), than after busulfan (n = 2) while all patients were rescued by second procedures except one busulfan patient. CTCAE Grade III adverse events were similar in both groups. This study confirmed treosulfan to be an excellent alternative to busulfan and can be safely used for conditioning treatment in children with non-malignant disease.

Published
2023
Full Text
View/download PDF

35. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study

Author

Averbuch, Dina, de la Camara, Rafael, Tridello, Gloria, Knelange, Nina Simone, Bykova, Tatiana A., Ifversen, Marianne, Dobsinska, Veronika, Ayas, Mouhab, Hamidieh, Amir Ali, Pichler, Herbert, Perez-Martinez, Antonio, Cesaro, Simone, Sundin, Mikael, Badell, Isabel, Bader, Peter, Johansson, Jan-Erik, Mirci-Danicar, Oana, Sedlacek, Petr, Paillard, Catherine, Gibson, Brenda, Lawson, Sarah, Kroeger, Nicolaus, Corbacioglu, Selim, Mikulska, Malgorzata, Piñana, Jose Luis, Styczynski, Jan, and Ljungman, Per

Abstract

Risk factors for severe SARS-Cov-2 infection course are poorly described in children following hematopoietic cell transplantation (HCT). In this international study, we analyzed factors associated with a severe course (intensive care unit (ICU) admission and/or mortality) in post-HCT children. Eighty-nine children (58% male; median age 9 years (min-max 1–18)) who received an allogeneic (85; 96%) or an autologous (4; 4%) HCT were reported from 28 centers (18 countries). Median time from HCT to SARS-Cov-2 infection was 7 months (min-max 0–181). The most common clinical manifestations included fever (37; 42%) and cough (26; 29%); 37 (42%) were asymptomatic. Nine (10%) children following allo-HCT required ICU care. Seven children (8%) following allo-HCT, died at a median of 22 days after SARS-Cov-2 diagnosis. In a univariate analysis, the probability of a severe disease course was higher in allo-HCT children with chronic GVHD, non-malignant disease, immune suppressive treatment (specifically, mycophenolate), moderate immunodeficiency score, low Lansky score, fever, cough, coinfection, pulmonary radiological findings, and high C-reactive protein. In conclusion, SARS-Cov-2 infection in children following HCT was frequently asymptomatic. Despite this, 10% needed ICU admission and 8% died in our cohort. Certain HCT, underlying disease, and SARS-Cov-2 related factors were associated with a severe disease course.

Published
2023
Full Text
View/download PDF

36. No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease

Author

Thiel, U., primary, Schober, S. J., additional, Ranft, A., additional, Gassmann, H., additional, Jabar, S., additional, Gall, K., additional, von Lüttichau, I., additional, Wawer, A., additional, Koscielniak, E., additional, Diaz, M. A., additional, Ussowicz, M., additional, Kazantsev, I., additional, Afanasyev, B., additional, Merker, M., additional, Klingebiel, T., additional, Prete, A., additional, Gruhn, B., additional, Bader, P., additional, Jürgens, H., additional, Dirksen, U., additional, Handgretinger, R., additional, Burdach, S., additional, and Lang, P., additional

Published
2021
Full Text
View/download PDF

38. Allo-SCT using BU, CY and melphalan for children with AML in second CR

Author

Beier, R, Albert, M H, Bader, P, Borkhardt, A, Creutzig, U, Eyrich, M, Ehlert, K, Gruhn, B, Greil, J, Handgretinger, R, Holter, W, Klingebiel, T, Kremens, B, Lang, P, Mauz-Körholz, C, Meisel, R, Müller, I, Peters, C, Reinhardt, D, Sedlacek, P, Schulz, A, Schuster, F R, Schrauder, A, Strahm, B, Sykora, K W, Wössmann, W, Zimmermann, M, and Sauer, M G

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results